Background: Naltrexone is a mu opiate receptor antagonist. In low dose, naltrexone has partial opiate agaonist properties and is anecdotally reported to improve MS quality of life. Objective: To determine whether 8 weeks of nightly 4.5 mg naltrexone improves MS quality of life. Methods: This is a single center, randomized, double masked, placebo controlled, double-cross over study of naltrexone (4.5mg daily) on MS quality of life as measured by the multiple sclerosis quality of life inventory (MSQLI). MSQLI questionnaire was administered to each subject at week zero, week 8 and week 17. Analysis used time series regression modeled for random effects and clustered by study subject and adjusted for sex, age, disease course, immunomodulator treatment, race, study drug order and baseline score.
Background:
A new formulation of subcutaneous (sc) interferon (IFN) beta-1a has been produced that is free from serum-derived products, with the aim of improving tolerability and reducing immunogenicity while maintaining efficacy. Objective: To evaluate the short-term efficacy of this new formulation of sc IFN beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS) using MRI. Methods: A Phase IIIb, multicentre study in adult patients with RRMS (McDonald criteria); EDSS score: ≤5.5; disease duration >12 months; presence of ≥1 clinical event and ≥1 brain gadolinium-enhancing (Gd-enhancing) MRI lesion(s) within the 6 months prior to randomization. Patients were randomized (2:1) to the new formulation of sc IFN beta-1a (Rebif®), 44 mcg three times weekly (tiw) (n=120), or placebo (n=60) for 16 weeks (double-blind phase). The primary endpoint was the number of combined unique active (CUA) brain lesions at week 16. A single-blind phase where all patients receive the new formulation of IFN beta-1a, 44 mcg sc tiw, for a further 24 weeks is ongoing. Results: Baseline demographics, MRI (T2-W and Gd-enhancing lesions) and disease characteristics were similar between groups. At week 16, mean (median) number of CUA lesions (primary outcome measure) was 0.9 (0) in the sc IFN beta-1a group and 3.0 (1) in the placebo group (nonparametric ANOVA: p<0.001). The ratio (95% CI) of means (sc IFN beta-1a / placebo), estimated using a negative binomial model, was 0.31 (0.21-0.45), indicating 69% fewer lesions with sc IFN beta-1a compared with placebo. The number of new T2-W and Gd-enhancing lesions during 16 weeks and the T2-W lesion volume at week 16 were also significantly lower with sc IFN beta-1a than placebo (p<0.001). Conclusions: This is the first double-blind, placebo-controlled study to demonstrate the rapid and beneficial treatment effects of the new formulation of sc IFN beta-1a in RRMS patients. Supported by: Merck Serono International S.A., an affiliate of Merck KGaA, Darmstadt, Germany. Ottawa, Ontario, Canada; 2 University Hospital, Basel, Switzerland; 3 Vrije Universiteit Medical Centre, Amsterdam, Netherlands; 4 Centre Hospitalier Universitaire, Rennes, France; Düsseldorf, Germany; 6 The National Hospital for Neurology and Neurosurgery, London, United Kingdom; 7 Hospital Vall d'Hebron, Barcelona, Spain; 8 Bayer Schering Pharma AG, Berlin, Germany Background: The BENEFIT study (BEtaferon® in Newly Emerging multiple sclerosis For Initial Treatment) was designed to evaluate the impact of early treatment initiation with interferon beta-1b (IFNB-1b; Betaferon®) in patients with a first event suggestive of MS. Objective: To present the 5-year results. Methods: In the placebo-controlled phase, patients were randomized to IFNB-1b 250 µg or placebo, sc eod, for 2 years or until clinically definite MS (CDMS), if earlier. Patients could then enroll in a follow-up phase and were offered, but not required to take, IFNB-1b. Patients and physicians remained blinded to the initial treatment allocation. Patients initially randomized to IFNB-1b are defined as "early treatment" group and those initially randomized to placebo as "delayed treatment". Primary outcome measures included time to CDMS and time to confirmed disability progression, measured by the EDSS. Analyses were prospectively planned at 3 and 5 years using a pre-defined hierarchical statistical analysis plan. Results: Of the 468 patients originally randomized (IFNB-1b 292, placebo 176), 358 (76%) were followed for 5 years. In line with the 3-year analysis, early treatment with IFNB-1b vs. delayed treatment reduced the risk of developing CDMS by 37% over 5 years (p=0.003) and led to an overall 20% reduction in relapse rate (p=0.015) as well as a significant reduction in new lesion formation. Early treatment reduced the risk of confirmed EDSS progression by 40% (p=0.0218) at 3 years; the respective risk reduction was 24% after 5 years, not reaching statistical significance. Quality of Life remained high and stable over time in both groups. At 3 (p=0.0106) and We conducted a pilot trial to compare the effect of GA 20 mg SC daily versus every other day (QOD) in RRMS. The primary endpoint was based on a composite of clinical, MRI, and immunologic outcomes. Methods: Treatment naïve RRMS patients were randomized to GA 20 mg SC QD or QOD and followed prospectively for 2 years. After 2 years, patients in each group were given the option to continue or switch to the other group, and followed for an additional 2 years. EDSS was recorded every 6 months by a rater blinded to dosing allocation. Brain MRI scans were obtained at baseline, and years 2 and 4. Blood for immunologic testing was obtained at baseline and multiple time points after randomization. Results: 30 patients were randomized to GA 20 mg SC given QD or QOD. Both groups were well-matched for age, disease duration, EDSS, relapse rate, T2W and gadolinium (Gd) enhancing lesions. After 2 years, there were no differences in the relapse rate, disease progression, Change in T2W lesion volume, or Gd enhancing lesions between the two groups. In vitro proliferation of GA-responsive T-cells and Th1/Th2 cytokine expression did not differ between the two groups at any time point after randomization. After 2 years, all patients in the QD group opted to switch to QOD. After a total of 4 years of prospective follow-up, there was no difference between the QD-QOD cross over group and the always QOD group. Additional data on imaging and immunologic outcomes will be presented.
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Impact of early interferon beta-1b treatment on disease evolution over five years in patients with a first event suggestive of multiple sclerosis
Conclusions:
This pilot study suggests that GA 20 mg SC administered QD or QOD may be equally effective in RRMS. This may have implications for the long-term use of GA. However, large multi-center studies are warranted to confirm our findings and to identify the optimal dose of GA in RRMS. and 24. Outcomes of interest were the annualized exacerbation rate (AER), change in EDSS and cerebral atrophy rate. By means of multiple linear regression analysis, baseline volume of gadolinium enhanced (Gd+) lesions, T2 lesions, T1-hypointense lesions, brain volume and on-study volume changes of Gd+ and T2 lesions during the first year of study were evaluated as possible predictors for clinical outcome and atrophy rate. Results: Gd+ and T2 lesion loads at baseline independently predicted AER during 2 year follow-up, corrected for (2 year) pre-trial exacerbation rate (p< 0.001 & p = 0.001, respectively). Volume change of on-study Gd+ lesions during the first year was also significantly related to the AER during the second year of follow-up (p=0.049). Black hole ratio (T1 hypo/T2) at baseline significantly predicted the change in EDSS at 2 year follow-up (p = 0.001). For atrophy rate over 2 years, we found a significant independent predictive value of Gd+ and T2 lesion volume at baseline (both p<0.001).
Epidemiology/Genetics
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The expanding genetic overlap between multiple sclerosis and type 1 diabetes
Interaction with treatment was negligible for almost all associations found. Conclusions: Various MRI parameters predicted on-study clinical outcomes, especially relapse related ones. Our findings support the use of MRI end-points in clinical trials in MS. Background: Axonal damage is the main cause for permanent disability in patients with multiple sclerosis (MS), the most common chronic inflammatory CNS disorder in young adults. The majority of studies in the past focussed on the involvement of CD4+ T cells in MS pathogenesis both in humans as well as in the animal model of MS, experimental autoimmune encephalomyelitis (EAE). Objective:
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Upper cervical cord atrophy reflects disease subtype and disability in patients with multiple sclerosis followed up 20 years from disease onset with a clinically isolated syndrome
Although several recent findings demonstrated the involvement of CD8+ T cells in MS and established a pathogenic role of myelinspecific CD8+ T cells in the animal model, mechanistic insights into CD8-driven CNS damage are lacking. Methods: To observe the interactions between antigen-specific T cells and their targets in living brain tissue, we applied a quasi-in vivo confocal imaging approach of organotypic brain slices derived from transgenic mice. In this setting, we used both CD8+ T cells (CTL) and CD4+ T cells carrying transgenic T cell receptors specific for the same antigen as effector cells. Results: While we could clearly demonstrate the capacity of CTLs to damage myelinated axons pulsed with cognate antigen, it remains unresolved to this date, whether axonal injury is the result of a targeted hit against the axon itself or the consequence of an attack against the myelin structure (collateral damage). To specifically answer this question, we next restricted the transgenic expression of the cognate antigen exclusively to the cytosol of oligodendrocytes. Conclusions: Here, we could unambigously show that axonal injury is the result of "collateral damage" by antigen-specific CTL targeting their cognate antigen presented by oligodendrocytes. Background: A prior Phase 3 study of sustained-release fampridine (4-aminopyridine) in MS showed beneficial effects on ambulation and leg strength. Objective: To confirm the efficacy and safety of fampridine (Fampridine-SR) in an independent study of patients with ambulatory deficits due to multiple sclerosis (MS). Methods: This was a randomized, double-blind, placebo-controlled, parallel-group study comparing 10 mg sustained-release fampridine bid and placebo. A 2-week placebo run-in was followed by 9 week treatment and 2 week follow-up periods. Eligibility criteria included: definite MS of any subtype; age 18-70; completion of the Timed 25-Foot Walk (T25FW) within 8-45 seconds at screening; stable concomitant medications. The pre-specified primary outcome was the proportion of patients with consistent improvement in walking speed on the T25FW during the treatment period (Timed Walk Responders). The clinical validity of the response criterion was previously established by correlation with the 12-Item MS Walking Scale, subject and clinician global impression scales. The secondary outcome was manually assessed leg strength, comparing Timed Walk Responders and Non-Responders with placebo-treated patients. Results: A total of 239 patients were randomized; 120 received fampridine and 119 placebo. 227 patients completed the trial (n = 113, 114). The fampridine-treated group had a higher proportion of Timed Walk Responders, compared to the placebo group (42.9 % v. 9.3 %; p<0.001) across all MS subtypes. Walking speed in Timed Walk Responders improved by approximately 25% from baseline, throughout the treatment period. Leg strength was significantly improved in Timed Walk Responders versus placebo-treated patients (p = 0.028). Adverse events were similar to those observed in previous studies of fampridine in MS. Three serious adverse events led to discontinuation, only one of which (patellar fracture) was in the fampridine group. Conclusions: Fampridine consistently improved walking speed and leg strength in a significant proportion of MS patients during 9 weeks of treatment. Supported by: Acorda Therapeputics, Inc., Hawthorne, NY, USA.
